SABCS 2020 | Phase III study of plinabulin and pegfilgrastim for chemotherapy-induced neutropenia

Douglas Blayney, MD, Stanford Cancer Institute, Stanford, CA, discusses the results of a randomized, Phase III study evaluating plinabulin and pegfilgrastim versus pegfilgrastim monotherapy for the prevention of chemotherapy-induced neutropenia after docetaxel, adriamycin, and cyclophosphamide chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).